Navigation Links
Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
Date:10/18/2010

Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo®... -- POINT RICHMOND, Calif., Oct. 18 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals Click to view news release full screen  

Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study

   

Call Scheduled for Tuesday, October 19, 2010 at 8:00 a.m. EDT

POINT RICHMOND, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that it will host a conference call to discuss the recently announced preliminary analysis of the Intermezzo® highway driving study.Conference Call Information Date: Tuesday, October 19, 2010Time: 8:00 a.m. ETDial-in (U.S.): 877-638-4558Dial-in (International): 914-495-8537A simultaneous web cast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until November 23, 2010.

A telephone replay of the conference call will be available shortly after the conclusion of the call until end of business October 23, 2010. The replay telephone numbers are 800-642-1687 (U.S.) and 706-645-9291 (International), replay passcode: 19398284.

About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  For further information, please visit the Transcept website at: www.transcept.com.

Contact:Transcept Pharmaceuticals, Inc.Greg MannDirector, Corporate Communications(510) 215-3567gmann@transcept.com
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals to Present at Newsmakers in the Biotech Industry Conference
2. Transcept Pharmaceuticals to Present at BIO Investor Forum
3. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
4. Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
5. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
6. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
7. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
8. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
9. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
10. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
11. Transcept Pharmaceuticals to Report First Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development of a once-daily, oral therapy for ... Chief Medical Officer, Dr. Maya Halpern , has notified ... Chief Medical Officer and from its Board of Directors ... reaching retirement age. Allen Baharaff . Mr. ...
(Date:2/11/2016)... February 11, 2016 North America ... published by MarketsandMarkets, The global market is expected to reach USD ... at a CAGR of 10.2%. --> North America ... 2020", published by MarketsandMarkets, The global market is expected to reach ... growing at a CAGR of 10.2%. --> According to ...
(Date:2/10/2016)... February 11, 2016 ... the "Molecular Diagnostics Reports Bundle" ... http://www.researchandmarkets.com/research/rp4pg8/molecular ) has announced the addition of ... report to their offering. --> ... announced the addition of the "Molecular ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... From ... American Academy of Dermatology Annual Meeting at the Walter E. Washington Convention Center ... awareness for both the condition of hyperhidrosis (excessive sweating) and its treatment options. ...
(Date:2/11/2016)... ... February 11, 2016 , ... Food Labeling ... in health and wellness best practices in the past couple of decades, and ... is American Heart Month, which acts as an exceptional opportunity to revise food ...
(Date:2/11/2016)... ... ... As part of their 2015 end of year funding strategy, Colleen’s ... gifted $10,000 to University of Chicago to support ovarian cancer research being conducted by ... honored to support a promising young investigator from Dr. Lengyel’s lab at the University ...
(Date:2/10/2016)... ... 10, 2016 , ... Sherly Sulaiman, certified clinical hypnotherapist and ... sessions to help Los Angeles-area actors cope with rejection, improve their auditions, and ... as “Mindfulness for Actors and Artists,” has been featured in Daily Actor ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
Breaking Medicine News(10 mins):